Skip to Main Content

A little more than one year ago, I wrote a skeptical article about Endocyte (ECYT), a small, down-on-its-luck biotech that had just licensed an experimental prostate cancer drug in what the CEO called a “transformational” transaction.

Endocyte shares popped from $1 to $4 on the September 2017 deal, which I called out as an over-hyped reaction to some overly promotional claims made by the company and CEO Mike Sherman. The excitement over that “transformational” prostate cancer drug was more likely to end in disappointment, I wrote.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.